Innovation Pharmaceuticals Inc represents values of innovation, progress, and growth in the pharmaceutical industry. The company's corporate philosophy revolves around developing novel and effective therapies to improve patients' lives. With a focus on research and development, Innovation Pharmaceuticals Inc strives to discover and advance breakthrough treatments for various diseases and medical conditions. This commitment to innovation and the pursuit of new solutions sets the company apart in the pharmaceutical sector. With a strong emphasis on scientific excellence, Innovation Pharmaceuticals Inc aims to make a positive impact on global healthcare.

Innovation Pharmaceuticals Inc is primarily present in the United States.

Innovation Pharmaceuticals Inc, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed phase 2 clinical trials for its flagship drug candidate, Brilacidin, which exhibited promising results in treating oral mucositis, a severe condition affecting cancer patients. Additionally, Innovation Pharmaceuticals Inc has obtained patents for Brilacidin in various countries, ensuring its market exclusivity. The company also established collaborations with prestigious research institutions and renowned healthcare organizations to advance its pipeline. With these accomplishments, Innovation Pharmaceuticals Inc has positioned itself as a key player in the pharmaceutical industry, revolutionizing patient care and offering hope for a better future.

Innovation Pharmaceuticals Inc. (Company) is a pharmaceutical company focused on the discovery and development of innovative therapies for various diseases. Established in [year], the company has built a strong foundation in research, working towards advancing treatment options for conditions such as cancer, autoimmune disorders, and antibiotic-resistant infections. With a team of dedicated scientists and industry experts, Innovation Pharmaceuticals Inc. strives to make a positive impact on healthcare worldwide. The company's commitment to innovation and scientific excellence has positioned them as a leading player in the pharmaceutical industry, continually aiming to improve patient outcomes through groundbreaking therapeutics.

The main competitors of Innovation Pharmaceuticals Inc in the market include biopharmaceutical companies such as Pfizer Inc., Johnson & Johnson, Novartis AG, and Merck & Co., Inc.

Innovation Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Innovation Pharmaceuticals Inc. focuses on the development and commercialization of innovative drug therapies. Through extensive research and collaboration with scientific experts, the company aims to discover and bring to market novel treatments for various diseases and medical conditions. Leveraging its expertise in pharmaceuticals, Innovation Pharmaceuticals Inc. seeks to improve patients' lives by advancing cutting-edge drug candidates and conducting clinical trials to demonstrate their efficacy and safety. This commitment to innovation and medical breakthroughs drives the company's business strategy and growth.

Innovation Pharmaceuticals için şu anki KGV hesaplanamıyor.

Innovation Pharmaceuticals için mevcut KUV şu anda hesaplanamıyor.

Innovation Pharmaceuticals için AlleAktien Kalite Skoru 2/10'dur.

Innovation Pharmaceuticals için şu an ciro hesaplanamıyor.

Innovation Pharmaceuticals için şu anda kar hesaplanamıyor.

Innovation Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing new therapeutics for the treatment of serious diseases. The company serves several areas, including oncology and dermatology. It is listed on the NASDAQ stock exchange under the ticker "IPIX" and has its headquarters in Beverly, Massachusetts. The core business of Innovation Pharmaceuticals Inc is to discover and develop new drugs and therapies to meet the needs of patients with serious illnesses. The company has an extensive pipeline of several products tailored to various medical needs. For example, Brilacidin, the company's flagship product, is an innovative drug developed for the treatment of skin and soft tissue infections. The company has also completed a phase III clinical trial for Brilacidin to treat oral mucositis in cancer patients and plans to submit an application for approval to the FDA. In addition to Brilacidin, Innovation Pharmaceuticals Inc is also developing other products. The company is working on a new drug for the treatment of thyroid carcinomas as well as a drug for the treatment of cystic fibrosis. Furthermore, the company has a wide range of patents and intellectual property related to the discovery and development of new therapeutics. To sell its products in the market, Innovation Pharmaceuticals Inc hopes for reliable collaboration with various companies that can market their products. The company has entered into an agreement with Alfasigma USA, Inc. for the sale of Brilacidin for topical use in skin and soft tissue infections in North America. A similar agreement with another company may also be pursued for the distribution of Brilacidin in other regions. In addition to direct marketing of its products and partnerships with other companies, Innovation Pharmaceuticals Inc also relies on collaboration with scientists, universities, and research institutions. The company believes in an open innovation strategy that allows for collaboration with other companies and research institutions to accelerate progress in drug development. Collaboration has led to several successful collaborations and partnerships in the medical field, earning Innovation Pharmaceuticals Inc a good reputation in the industry. Innovation Pharmaceuticals Inc is an emerging biopharmaceutical company that focuses on developing new and innovative therapeutics to combat serious diseases. The company has an extensive pipeline of product candidates for various medical areas and is actively working on marketing its products and collaborating with other companies and research institutions. With a strong focus on innovation in drug development, Innovation Pharmaceuticals Inc is well positioned to achieve further notable successes in the industry in the future.

Innovation Pharmaceuticals, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Innovation Pharmaceuticals için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Innovation Pharmaceuticals şirketinin ISIN kodu US45782D1000’dir.

Innovation Pharmaceuticals 'nin WKN'si A2DTBJ 'dir.

Innovation Pharmaceuticals için Ticker IPIX’dir.

Son 12 ay içerisinde Innovation Pharmaceuticals, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Innovation Pharmaceuticals, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Innovation Pharmaceuticals şirketinin mevcut temettü verimi .

Innovation Pharmaceuticals dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Innovation Pharmaceuticals, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Innovation Pharmaceuticals, 'Sağlık' sektörüne atanmıştır.

Son Innovation Pharmaceuticals tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 01.11.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 01.11.2024 olarak gerçekleşti.

2023 yılında Innovation Pharmaceuticals tarafından 0 USD olarak temettüler dağıtıldı.

Innovation Pharmaceuticals hisselerinin temettüleri USD olarak dağıtılır.